PW Medtech Group Limited (HKG:1358)

PW Medtech Group Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	94.37	150.78	153.18	106.04	739.12
Depreciation & Amortization	139.84	117.73	98.24	78.58	31.41
Other Amortization	0.02	0.02	0.02	0.01	0
Loss (Gain) From Sale of Assets	0.07	0.11	7.14	0.01	-731.79
Asset Writedown & Restructuring Costs	1.82	1.18	0.06	11.65	52.59
Loss (Gain) From Sale of Investments	-5.95	-0.37	-	-	-
Stock-Based Compensation	26.45	18.6	-	-	-
Provision & Write-off of Bad Debts	-6.5	-2.67	-4.17	-2.72	1.14
Other Operating Activities	-11.17	-14.11	-23.24	57.2	-66.98
Change in Accounts Receivable	16.25	-1.59	-11.49	-28.46	3.71
Change in Inventory	-27.33	15.24	-4.57	-5.46	5.86
Change in Accounts Payable	15.78	7.4	5.65	40.42	2.82
Change in Unearned Revenue	9.83	10.58	-5.09	7.26	-0.64
Change in Other Net Operating Assets	-12.78	15.54	-	-	-
Operating Cash Flow	240.7	318.43	211.03	269.23	37.24
Operating Cash Flow Growth	-24.41%	50.89%	-21.62%	622.91%	-52.38%

Investing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-90.05	-56.5	-47.31	-52.46	-11.32
Sale of Property, Plant & Equipment	2.62	0.55	3.7	0.11	0.14
Cash Acquisitions	-	-	-	-1,014	-
Divestitures	-	-	35.99	-	-
Sale (Purchase) of Intangibles	-15.01	-15.58	-34.61	-9.4	-
Sale (Purchase) of Real Estate	-	0.82	-	-	-
Investment in Securities	4.37	-0.25	0.73	48.83	2,770
Other Investing Activities	44.78	50.65	43.83	35.37	57.34
Investing Cash Flow	6.71	-20.32	-26.67	-1,082	2,636

Financing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	9.2	5.8	-	-	-
Total Debt Issued	9.2	5.8	-	-	-
Long-Term Debt Repaid	-2.13	-1.5	-0.67	-83.64	-28.42
Total Debt Repaid	-2.13	-1.5	-0.67	-83.64	-28.42
Net Debt Issued (Repaid)	7.07	4.3	-0.67	-83.64	-28.42
Repurchase of Common Stock	-19.76	-80.22	-	-3.06	-
Common Dividends Paid	-130.35	-134.37	-71.6	-	-2,062
Other Financing Activities	16.53	-0.37	89.8	1.54	-0.6
Financing Cash Flow	-126.51	-210.66	17.53	-85.16	-2,091

Net Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.05	4.89	5.84	-4.6	0.63
Net Cash Flow	120.86	92.33	207.74	-902.86	582.99

Free Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	150.66	261.93	163.73	216.77	25.92
Free Cash Flow Growth	-42.48%	59.98%	-24.47%	736.25%	-63.14%
Free Cash Flow Margin	18.30%	34.06%	24.25%	40.38%	9.55%
Free Cash Flow Per Share	0.10	0.17	0.10	0.14	0.02
Levered Free Cash Flow	16.94	229.72	233.51	-236.55	2,229
Unlevered Free Cash Flow	17.39	229.95	233.6	-236.26	2,229

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	0.72	0.37	0.15	0.46	0.6
Cash Income Tax Paid	41.25	36.97	44.56	14.33	7.01
Change in Working Capital	1.75	47.17	-15.5	13.76	11.74

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 19, 2026

Data Sources Report a data error